Back to News
Market Impact: 0.4

PostNL Q3 loss widens on weak mail volumes, higher costs

PTNLSMCIAPP
Corporate EarningsCompany FundamentalsCorporate Guidance & OutlookRegulation & LegislationCredit & Bond MarketsESG & Climate PolicyTransportation & Logistics
PostNL Q3 loss widens on weak mail volumes, higher costs

PostNL reported a wider third-quarter operating loss of €21 million, compared to a €18 million loss a year prior, despite a slight revenue increase to €762 million, as higher costs and declining mail volumes outweighed modest 1.0% parcel growth. The Dutch mail and parcel company's CEO emphasized the need for postal regulation changes due to ongoing mail volume substitution and a less favorable customer mix in domestic parcels, even as free cash flow improved to a negative €18 million. PostNL reaffirmed its full-year 2025 outlook for normalized EBIT to be in line with 2024's €53 million, anticipating a stronger fourth-quarter contribution.

Analysis

PostNL reported a wider operating loss of €21 million in Q3 2025, compared to a €18 million loss a year prior, despite a slight revenue increase to €762 million from €756 million. This deterioration was primarily driven by higher costs and a 5.0% decline in Mail in the Netherlands volumes due to ongoing substitution, which offset modest 1.0% parcel growth. Year-to-date, normalised EBIT also widened to a €26 million loss from a €9 million loss, indicating persistent operational challenges. The Parcels segment saw revenue rise to €581 million, but normalised EBIT declined to €4 million from €6 million, impacted by a less favorable customer mix despite 5% growth from international customers. CEO Pim Berendsen highlighted that the €43 million normalised EBIT loss for Mail in the Netherlands year-to-date underscores the critical need for postal regulation changes, stating the government's proposed D+2/D+3 delivery framework is insufficient to offset net costs. This regulatory environment remains a significant headwind for the Mail division. PostNL's financial health shows increased leverage, with adjusted net debt rising to €572 million from €474 million at year-end 2024, and consolidated equity declining to €128 million from €202 million, partly due to a €40 million goodwill impairment in Q2. Despite these pressures, free cash flow improved to a negative €18 million from a negative €68 million year-over-year, largely due to timing effects. The company reaffirmed its full-year 2025 outlook, expecting normalised EBIT in line with 2024's €53 million and free cash flow between negative €10 million and negative €50 million, anticipating a seasonally stronger Q4.